Rights and permissions
About this article
Cite this article
Telithromycin potentially cost saving in patients with AECB. Pharmacoecon. Outcomes News 434, 3–4 (2003). https://doi.org/10.1007/BF03276889
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03276889